Questionnaire and diary are encrypted with your password and stored only in this browser. The site owner does not receive them.
Triple Agonist Mechanism of Action (LY3437943)
Retatrutide (LY3437943) is a first-in-class peptide single-molecule tri-agonist targeting GIP, GLP-1, and Glucagon receptors. Synergistic activation of all three pathways delivers unprecedented energy expenditure enhancement, profound appetite suppression, and up to 86% hepatic fat reduction.
Glucose-dependent Insulinotropic Polypeptide Receptor (GIP)
- Glucose-dependent insulin secretion stimulation
- Pancreatic beta-cell protection & preservation
- Improved lipid metabolism & adipocyte insulin sensitivity
- Synergistic appetite suppression with GLP-1
Glucagon-like Peptide-1 Receptor (GLP-1)
- Delayed gastric emptying & increased satiety
- Glucose-dependent blood sugar reduction
- Glucagon secretion suppression during hyperglycemia
- Central reduction of high-calorie food cravings
Glucagon Receptor (GCG)
- Increased resting energy expenditure (basal metabolic rate)
- Hepatic fatty acid oxidation & lipolysis stimulation
- Dramatic reduction in liver fat content (up to -86%)
- Thermogenesis activation in brown/white adipose tissue
Triple Agonism Synergy: Why Retatrutide Outperforms Dual Agonists?
1. Overcoming Metabolic Adaptation (Weight Loss Plateau)
During prolonged weight loss on mono GLP-1 therapies, resting metabolic rate slows down (adaptive thermogenesis). Adding Glucagon receptor agonism in Retatrutide directly stimulates hepatic fatty acid oxidation, maintaining high energy expenditure throughout treatment.
2. Direct Hepatic Fat Elimination (MASH / NAFLD)
Phase 2 substudies using MRI-PDFF demonstrated a mean relative liver fat content reduction of -86% at 24 weeks. Over 80% of participants with fatty liver disease achieved complete normalization of liver fat (< 5%).